Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC 85 3-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates XPAE:BPC with a GF Score™ of 85/100 and a GF Value™ of $4.33 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 645 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks worse than 155038.6% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Birzeit Pharmaceutical Co's current 3-Year Share Buyback Ratio was 0.00%.
The historical rank and industry rank for Birzeit Pharmaceutical Co's 3-Year Share Buyback Ratio or its related term are showing as below:
During the past 13 years, Birzeit Pharmaceutical Co's highest 3-Year Share Buyback Ratio was 0.40%. The lowest was -15.60%. And the median was 0.00%.
XPAE:BPC's 3-Year Share Buyback Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: -2.1 * Ranked among companies with meaningful 3-Year Share Buyback Ratio only.
Birzeit Pharmaceutical Co (XPAE:BPC) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Birzeit Pharmaceutical Co 3-Year Share Buyback Ratio Related Terms
XPAE:BPC vs ZTS, UTHR, VTRS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's 3-Year Share Buyback Ratio falls into.
Birzeit Pharmaceutical Co 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.00 mean?
Birzeit Pharmaceutical Co (XPAE:BPC) has a 3-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Birzeit Pharmaceutical Co and its competitors. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #999999 out of 645 companies in the Drug Manufacturers industry.
Is Birzeit Pharmaceutical Co's 3-Year Share Buyback Ratio too high?
Birzeit Pharmaceutical Co's current 3-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #999999 out of 645 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's 3-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #999999 out of 645 companies for 3-Year Share Buyback Ratio. This places Birzeit Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Birzeit Pharmaceutical Co and its competitors. Birzeit Pharmaceutical Co's current 3-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.33, compared to a current price of $3.77 — trading 12.9% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.00. Birzeit Pharmaceutical Co's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current 3-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.77 is trading 12.9% below its estimated GF Value™ of $4.33.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
3-Year Share Buyback Ratio: 0.00
GF Value™: $4.33 vs. price of $3.77 (12.9% below fair value)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
85GF Score
Get the complete analysis for XPAE:BPC
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
